Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters

Osteoporosis is a complication of type 2 diabetes mellitus (T2DM). Blockade of receptor activator of nuclear factor kappa-B ligand (RANKL) improves osteoporosis, but might also improve glucose tolerance through reduction of hepatic insulin resistance. However, the effect of denosumab (a human monocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Ichiro, Ochi, Kentaro, Takashi, Yuichi, Yamao, Yuka, Ohishi, Hanako, Fujii, Hideyuki, Minezaki, Midori, Sugimoto, Kaoru, Kudo, Tadachika, Abe, Makiko, Ohnishi, Yasushi, Mukoubara, Shigeaki, Kobayashi, Kunihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882599/
https://www.ncbi.nlm.nih.gov/pubmed/31764838
http://dx.doi.org/10.1097/MD.0000000000018067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882599/
https://www.ncbi.nlm.nih.gov/pubmed/31764838
http://dx.doi.org/10.1097/MD.0000000000018067

Ejemplares similares